KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial.

Sumathi Sivapalasingam, David J Lederer, Rafia Bhore, Negin Hajizadeh, Gerard Criner, Romana Hosain, Adnan Mahmood, Angeliki Giannelou, Selin Somersan-Karakaya, Meagan P O'Brien, Anita Boyapati, Janie Parrino, Bret J Musser, Emily Labriola-Tompkins, Divya Ramesh, Lisa A Purcell, Daya Gulabani, Wendy Kampman, Alpana Waldron, Michelle Ng Gong, Suraj Saggar, Steven J Sperber, Vidya Menon, David K Stein, Magdalena E Sobieszczyk, William Park, Judith A Aberg, Samuel M Brown, Jack A Kosmicki, Julie E Horowitz, Manuel A Ferreira, Aris Baras, Bari Kowal, A Thomas DiCioccio, Bolanle Akinlade, Michael C Nivens, Ned Braunstein, Gary A Herman, George D Yancopoulos, David M Weinreich

Clin Infect Dis 75(1) e380-e388

PMID35219277
PMCIDPMC8903479
DOI10.1093/cid/ciac153
发表日期2022-02-26
摘要

摘要

BACKGROUND: Open-label platform trials and a prospective meta-analysis suggest efficacy of anti-interleukin (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 (COVID-19) receiving corticosteroids. This study evaluated the efficacy and safety of sarilumab, an anti-IL-6R monoclonal antibody, in the treatment of hospitalized patients with COVID-19. METHODS: In this adaptive, phase 2/3, randomized, double-blind, placebo-controlled trial, adults hospitalized with COVID-19 received intravenous sarilumab 400 mg or placebo. The phase 3 primary analysis population included patients with critical COVID-19 receiving mechanical ventilation (MV). The primary outcome was proportion of patients with ≥1-point improvement in clinical status from baseline to day 22. RESULTS: There were 457 and 1365 patients randomized and treated in phases 2 and 3, respectively. In phase 3, patients with critical COVID-19 receiving MV (n = 298; 28.2% on corticosteroids), the proportion with ≥1-point improvement in clinical status (alive, not receiving MV) at day 22 was 43.2% for sarilumab and 35.5% for placebo (risk difference, +7.5%; 95% confidence interval [CI], -7.4 to 21.3; P =.3261), a relative risk improvement of 21.7%. In post hoc analyses pooling phase 2 and 3 critical patients receiving MV, the hazard ratio for death for sarilumab vs placebo was 0.76 (95% CI, .51 to 1.13) overall and 0.49 (95% CI, .25 to .94) in patients receiving corticosteroids at baseline. CONCLUSIONS: This study did not establish the efficacy of sarilumab in hospitalized patients with severe/critical COVID-19. Post hoc analyses were consistent with other studies that found a benefit of sarilumab in patients receiving corticosteroids. CLINICAL TRIALS REGISTRATION: NCT04315298.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。